Tradipitant Explained

Image Class:skin-invert-image
Width:150
Tradename:Nereus
Dailymedid:Tradipitant
Routes Of Administration:By mouth
Class:Neurokinin NK1 antagonist
Atc Prefix:None
Legal Us:Rx-only
Legal Us Comment:[1]
Cas Number:622370-35-8
Pubchem:9916461
Drugbank:DB12580
Chemspiderid:8092108
Unii:NY0COC51FI
Kegg:D11728
Chembl:3544984
Synonyms:VLY-686, LY686017
Iupac Name:(2-(1-(3,5-Bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone
C:28
H:16
Cl:1
F:6
N:5
O:1
Smiles:Clc1ccccc1C(=O)c2c(nccc2)c3nnn(c3c4ccncc4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F
Stdinchi:1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
Stdinchikey:CAVRKWRKTNINFF-UHFFFAOYSA-N

Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). It is a neurokinin 1 receptor antagonist. It works by blocking substance P, a small signaling molecule. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[2]

Tradipitant was approved for medical use in the United States in December 2025.[3]

Medical uses

Tradipitant is indicated for the prevention of vomiting induced by motion.

Society and culture

Legal status

Tradipitant was approved for medical use in the United States in December 2025.[4]

Names

Tradipitant is the international nonproprietary name.[5]

Tradipitant is sold under the brand name Nereus.

External links

Notes and References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220152Orig1s000lbl.pdf
  2. Web site: Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686. Bloomberg Business. 16 November 2015.
  3. Web site: Novel Drug Approvals for 2025 . U.S. Food and Drug Administration (FDA) . 2 January 2026 . 10 January 2026.
  4. Vanda Pharmaceuticals Announces FDA Approval of Nereus (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness . Vanda Pharmaceuticals . PR Newswire . 30 December 2025 . 10 January 2026.
  5. 2015 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73 . WHO Drug Information . 29 . 1 . 10665/331088 . free .